Adaptimmune Announces Q1 2024 Financial and Business Updates Presentation on May 15, 2024

Adaptimmune Therapeutics plc, a pioneering company in the field of cell therapy for solid tumor cancers, is set to announce its financial results and business updates for the first quarter of 2024 on May 15th. The company will release the information before the US markets open and will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day.

Adaptimmune is known for its innovative approach to treating cancer using engineered T-cell receptor (TCR) technology. This platform allows the company to design personalized therapies that target and destroy cancer cells in various types of solid tumors.

Investors and stakeholders can access the press release and webcast on Adaptimmune’s corporate website. The live webcast and replay will be available at https://www.gowebcasting.com/13334. For those interested in joining the call, the dial-in information is as follows: 1-800-806-5484 (US or Canada) or +416-340-2217 (International), with the passcode 3025919#.

Adaptimmune’s mission is to transform the lives of cancer patients through innovative cell therapies. The company’s dedication to advancing the field of oncology and improving patient outcomes is evident in its ongoing research and development efforts.

For more information about Adaptimmune and its upcoming financial report, interested parties can visit the company’s website or contact the Investor Relations or Media Relations representatives listed in the press release. Stay tuned for the latest updates on Adaptimmune’s groundbreaking work in the fight against cancer.